The Otsuka group's pharmaceutical business focuses on the core areas of the central nervous system and oncology in order to address unmet medical needs. Additionally, the group is engaged in a wide range of other fields and businesses, including the cardiovascular system, gastroenterology, ophthalmology, diagnostics, and the clinical nutrition and medical device businesses in order to provide comprehensive healthcare solutions ranging from diagnosis to the treatment of disease.
Guided by our corporate philosophy, "Otsuka-people creating new products for better health worldwide", Otsuka is committed to improving the health and well-being of patients and consumers through advancements in the "treatment of diseases" and "promotion of daily health". As a total healthcare company, Otsuka continues to focus on creating original and innovative products. In order to address unmet needs in medicine, we focus our research on central nervous system disorders and oncology, and also develop treatments in cardiovascular-renal, infectious, ophthalmological, and dermatological disease fields.
Our R&D philosophy places emphasis on encouraging individual researchers to take the untraveled path, pursuing new categories with fresh ideas.
Taiho Pharmaceutical conducts pharmaceutical research and development specializing in the areas of oncology, allergy/immunology, and urology. The company has Discovery and Preclinical Research Division (Tsukuba Area) as base for drug discovery research which has created a research network closely coordinated with the Discovery and Preclinical Research Division (Tokushima Area) and the Clinical Development & Medical Affairs Division in order to establish an R&D system focused on new medical treatment. In the field of oncology, which is the company's foremost field of endeavor, Taiho Pharmaceutical carries out global development of its mainstay anticancer agents in Japan, the U.S., Europe and Asia and engages in R&D with the aim of providing innovative new drugs to the world.
Otsuka Pharmaceutical Factory
Otsuka Pharmaceutical Factory (OPF) has engaged in the IV business for over 70 years. OPF led the development of IV products in Japan as a leading company of IV solutions which are considered to support the basis for medical treatment. Utilizing the development capability we have built up, at present we engage in R&D to develop products which create new value by meeting unmet medical needs in the fields of surgical aid and regenerative medicine products as well as in the field of clinical nutrition. For example, we are developing a bioengineered pancreatic islet product which could become a major treatment for diabetes patients. We see things from the patient's point of view and develop innovative products which are required in clinical practice without being bound by the constraints of existing concepts.